ЕРЛОТИНІБ-МІЛІ-150

ਉਤਪਾਦ ਝਲਕ

About ЕРЛОТИНІБ-МІЛІ-150

ЕРЛОТИНІБ-МІЛІ-150 is a prescription medication containing the active ingredient Erlotinib, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by blocking the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby inhibiting the growth and spread of cancer cells.

Key Benefits & Uses

• Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
• Treatment of pancreatic cancer
• May be used in combination with other medications for the treatment of NSCLC

Active Ingredient & Action

Erlotinib, the active ingredient in ЕРЛОТИНІБ-МІЛІ-150, is a small molecule inhibitor that selectively targets the EGFR tyrosine kinase. By binding to the ATP-binding site of the EGFR tyrosine kinase, Erlotinib prevents the phosphorylation of downstream signaling molecules, thereby inhibiting the growth and survival of cancer cells.

Important Notes

ЕРЛОТИНІБ-МІЛІ-150 is available only by prescription and should be used under the guidance of a qualified healthcare professional. Patients with a history of interstitial lung disease or radiation pneumonitis may be at increased risk of developing severe pulmonary toxicity. Regular monitoring of liver function and skin rash is recommended during treatment with ЕРЛОТИНІБ-МІЛІ-150.